These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 798203)

  • 1. Angiotensin antagonists as diagnostic and pharmacologic tools.
    Pettinger WA; Mitchell HC
    Prog Biochem Pharmacol; 1976; 12():203-13. PubMed ID: 798203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of saralasin in the recognition of angiotensinogenic hypertension.
    Streeten DH; Dalakos TG; Anderson GH
    Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of renin-angiotensin system inhibitors in the diagnosis of hypertension].
    Stumpe KO; Kolloch RE; Overlack A
    Med Welt; 1977 Oct; 28(41):1645-9. PubMed ID: 927124
    [No Abstract]   [Full Text] [Related]  

  • 5. Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man.
    Pettinger WA; Mitchell HC
    N Engl J Med; 1975 Jun; 292(23):1214-7. PubMed ID: 236513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Saralasin test, renal vein renin and unilateral kidney blood flow in renovascular hypertension].
    Helber A; Hummerich W; Bönner G; Meurer KA; Moritz G
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():208-9. PubMed ID: 613575
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypertension, the adrenal and the kidney: lessons from pharmacologic interruption of the renin-angiotensin system.
    Hollenberg NK; Williams GH
    Adv Intern Med; 1980; 25():327-61. PubMed ID: 6153859
    [No Abstract]   [Full Text] [Related]  

  • 8. [Does the recent knowledge on the renin-angiotensin system have clinical applications?].
    Maxwell M; Ducrot H; Meyer P; Richet G; Péquignot H
    Presse Med (1893); 1968 Nov; 76(47):2229-31. PubMed ID: 4305139
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of saralasin to evaluate the function of the brain renin-angiotensin system.
    Reid IA
    Prog Biochem Pharmacol; 1976; 12():117-34. PubMed ID: 1019160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of angiotensin antagonists.
    Pettinger WA; Mitchell HC
    Fed Proc; 1976 Nov; 35(13):2521-5. PubMed ID: 976494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient experience with saralasin.
    Streeten DH; Anderson GH
    Kidney Int Suppl; 1979 Mar; (9):S44-52. PubMed ID: 289863
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of biological effects of three angiotensin II antagonists in sodium depleted hypertensive patients.
    Ogihara T; Nakamaru M; Higaki J; Hata T; Kumagai A; Kumahara Y
    Med J Osaka Univ; 1983 Sep; 34(1-2):21-5. PubMed ID: 6366501
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical evaluation of renovascular hypertension and therapeutic decisions.
    Vaughan ED; Case DB; Pickering TG; Sosa RE; Sos TA; Laragh JH
    Urol Clin North Am; 1984 Aug; 11(3):393-407. PubMed ID: 6205495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New concepts of the renin system and of vasoconstriction-volume mechanisms. Diagnosis and treatment of renovascular and renal hypertensions.
    Vaughan EF; Laragh JH
    Urol Clin North Am; 1975 Jun; 2(2):237-57. PubMed ID: 1098253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renin, angiotensin, aldosterone and arterial hypertension. II].
    Maxwell MH
    Presse Med (1893); 1969 Dec; 77(55):2107-10. PubMed ID: 4313755
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug interactions with saralasin.
    Mitchell HC; Keeton TK; Pettinger WA
    Kidney Int Suppl; 1979 Mar; (9):S101-6. PubMed ID: 289859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of an angiotensin antagonist on blood pressure, renin and aldosterone secretion and its pathogenetic importance].
    Beckerhoff R
    Schweiz Med Wochenschr Suppl; 1978; (7):1-24. PubMed ID: 349683
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypertension screening and treatment with angiotensin inhibitors. Saralasin and captopril.
    Zawada ET; Stinson J; Ramirez G
    Postgrad Med; 1980 Oct; 68(4):89-92, 94-5, 98. PubMed ID: 6999479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacologic functional examination in arterial hypertension].
    Stumpe KO; Kolloch R; Overlack A
    Internist (Berl); 1977 Nov; 18(11):594-600. PubMed ID: 23361
    [No Abstract]   [Full Text] [Related]  

  • 20. Vasodilating antihypertensive drug-induced aldosterone release--a study of endogenous angiotensin-mediated aldosterone release in the rat.
    Campbell WB; Pettinger WA; Keeton K; Brooks SN
    J Pharmacol Exp Ther; 1975 Apr; 193(1):166-75. PubMed ID: 1167223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.